Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy

NEXT STORY
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
PREV STORY
Global Nasal Swab Test Market Size Is Expected To Reach Around USD 150.7 Million by 2026, at a CAGR of 3.4% Growth: Facts & Factors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer

author_avatar
NASDAQ Market News

Cerner, AANAC Award Nursing Assistant of the Year Scholarship

KANSAS CITY, Mo., May 26, 2017 (GLOBE NEWSWIRE) -- Cerner, a global leader in ...

author_avatar
NASDAQ Market News

Zenith Epigenetics Announces Clinical Advancement of ZEN-3694

author_avatar
NASDAQ Market News